After-Hours Movers 6/30: OSK, SNX Higher; FRPT, MYGN, ZZ, SQNM Lower
More News related to AMAG
- Baird Reiterates an 'Outperform' on AMAG Pharmaceuticals (AMAG); Incrementally Positive on CMS News
- AMAG Pharma (AMAG) Posts Q3 Loss of $1.29
- AMAG Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2009
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
- AMAG Pharmaceuticals, Inc. to Host Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2009
More News related to FRPT
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
- Force Protection to Announce Third Quarter Fiscal 2009 Results
- Notable Analyst Rating Changes 10/01: AA, CHU, BIG, BHI, OMX, FRPT Upgraded; SKS, RVSN, KBH, NVDA, PMCS, A Downgraded
- Collins Stewart Upgrades Force Protection (FRPT) to Buy; Adjusts 2009-10 Estimates
- Force Protection (FRPT) Initiates Significant Program of Operational Realignment and Overhead Reductions
More News related to MYGN
- Myriad Genetics to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
- After-Hours Movers 11/03: QLTY, PACR, BGCP, TESO Higher; STEC, TRLG, CLRT, CRL, MYGN Lower
- Myriad Genetics (MYGN) Misses Q1 EPS by 3c
- Myriad Genetics Reports First Quarter Fiscal 2010 Financial Results
- Trading Radar for 11/03: UBS (UBS), Yamana Gold (AUY), Archer-Daniels (ADM), Royal Caribbean (RCL), Marathon (MRO) Report
Force Protection Inc. (Nasdaq: FRPT) 24% LOWER; sinking on news Oshkosh has won a contract for blast-proof trucks.
Oshkosh Corporation (NYSE: OSK) 23% HIGHER; wins $1.06 billion contract for blast-proof truck, according to a source from the Pentagon. Click here for the full report.
Myriad Genetics, Inc. (NASDAQ: MYGN) 17% LOWER; announced that, based on preliminary estimates, it anticipates reporting total molecular diagnostic revenue, which represents the bulk of the Company's revenue, of approximately $86 million for the fiscal 2009 fourth quarter ending June 30, 2009. (Consensus is $91.63M)
Sealy Corp. (NYSE: ZZ) 6.6% LOWER; reports Q2 EPS of $0.07, ex-items, versus the analyst estimate of $0.05. Revenue for the quarter was $298.5 million, versus the consensus of $298.14 million.
Sequenom (Nasdaq: SQNM) 5.8% LOWER; disclosed that on June 29, 2009, it received written notification that the SEC has initiated an investigation relating to our April 29, 2009 announcement regarding it's SEQureDx Down syndrome test. Sequenom said it intends to cooperate fully with the SEC in this matter and that its internal investigation is ongoing.
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) 4.5% HIGHER; said the FDA has granted marketing approval for Feraheme Injection for intravenous (IV) use as an iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease. Click here for the full report.
SYNNEX Corporation (NYSE: SNX) 3.7% HIGHER; reports Q2 EPS of $0.57, versus the analyst estimate of $0.48. Revenue for the quarter was $1.81 billion, versus the consensus of $1.68 billion. Sees Q3 sales of $1.8-$1.9 billion, versus the consensus of $1.75 billion, and EPS of $0.58-$0.61, versus the Street estimate of $0.51.
To get this report daily, visit http://www.streetinsider.com/entities/After-Hours+Movers.
Related Categories
Special ReportsStocks Mentioned
+2.27
-0.02Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
